DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers

Breast Cancer Research and Treatment

Volumn 152, Issue 2, 2015, Pages 271-282

  Vaclová, Tereza ^a   Gómez López, Gonzalo ^a   Setién, Fernando ^b   Bueno, José María García ^c   Macías, José Antonio ^d   Barroso, Alicia ^a   Urioste, Miguel ^a   Esteller, Manel ^b,e,f   Benítez, Javier ^a,g   Osorio, Ana ^a,g  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

BRCA1; Breast cancer; DNA repair; Gene expression profiling; Haploinsufficiency

Indexed keywords

BRCA1 PROTEIN; RAD51 PROTEIN; HISTONE; TRANSCRIPTOME;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LYMPHOBLASTOID CELL; LYMPHOBLASTOID CELL LINE; MICROARRAY ANALYSIS; MISSENSE MUTATION; NONSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CLUSTER ANALYSIS; GENE REGULATORY NETWORK; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ALLELES; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DNA REPAIR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HAPLOINSUFFICIENCY; HETEROZYGOTE; HISTONES; HUMANS; MUTATION; RAD51 RECOMBINASE; TRANSCRIPTOME;

EID: 84946491386     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3459-3     Document Type: Article

References (36)

1. Zhang J, Powell SN (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3:531–539
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130
3. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871
4. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, Sanchez-de-Abajo A, Caldes T et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14:2861–2869
5. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823
6. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428–433
7. Thompson D, Easton D, Breast Cancer Linkage Consortium (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336
8. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A et al (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20:797–809
9. Waddell N, Ten Haaf A, Marsh A, Johnson J, Walker LC, kConfab Investigators, Gongora M, Brown M, Grover P, Girolami M, Grimmond S, Chenevix-Trench G et al (2008) BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression. PLoS Gen 4:e1000080
10. Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, Rapakko K, Nieminen P, Xia B, Pospiech H, Winqvist R (2013) Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 4:2578
11. Grasso F, Giacomini E, Sanchez M, Degan P, Gismondi V, Mazzei F, Varesco L, Viel A, Bignami M (2014) Genetic instability in lymphoblastoid cell lines expressing biallelic and monoallelic variants in the human MUTYH gene. Hum Mol Genet 23:3843–3852
12. Kote-Jarai Z, Williams RD, Cattini N, Copeland M, Giddings I, Wooster R, tePoele RH, Workman P, Gusterson B, Peacock J, Gui G, Campbell C et al (2004) Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin Cancer Res 10:958–963
13. Kote-Jarai Z, Matthews L, Osorio A, Shanley S, Giddings I, Moreews F, Locke I, Evans DG, Eccles D, Carrier Clinic C, Williams RD, Girolami M et al (2006) Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin Cancer Res 12:3896–3901
14. Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS et al (2010) Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res 3:48–61
15. Feilotter HE, Michel C, Uy P, Bathurst L, Davey S (2014) BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development. PLoS One 9:e100068
16. Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T (2013) Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling. Cancer Prev Res 6:82–90
17. Conti E, Izaurralde E (2005) Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol 17:316–325
18. Okada S, Ouchi T (2003) Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. J Biol Chem 278:2015–2020
19. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P (1997) Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ 8:801–809
20. Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S (2006) The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 27:1024–1029
21. Roy R, Chun J, Powell SN (2011) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12:68–78
22. Mulrane L, McGee SF, Gallagher WM, O’Connor DP (2013) miRNA dysregulation in breast cancer. Cancer Res 73:6554–6562
23. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11:2805–2814
24. Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S (2008) Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat 29:65–73
25. Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43:74–83
26. Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J (2013) A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov 3:1142–1155
27. Cousineau I, Belmaaza A (2007) BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 6:962–971
28. Huszno J, Budryk M, Kolosza Z, Nowara E (2013) The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 85:278–282
29. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM (2001) Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 20:8215–8235
30. Sylvain V, Lafarge S, Bignon YJ (2002) Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 20:845–853
31. You F, Chiba N, Ishioka C, Parvin JD (2004) Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells. Oncogene 23:5792–5798
32. Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M, Vaux DJ (2011) A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 192:497–512
33. Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ (2011) Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res 13:R111
34. Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, Schneider M, SenGupta SK, Gonzalez FJ, Nicol CJ (2012) Stromal adipocyte PPARgamma protects against breast tumorigenesis. Carcinogenesis 33:1412–1420
35. Apostoli AJ, Skelhorne-Gross GE, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, SenGupta SK, Nicol CJ (2014) Loss of PPARgamma expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer 134:1055–1066
36. Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C (2010) The c.5242C > A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 120:391–399